Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

the Geriatric Depression Scale (GDS), first created by Yesavage et al., has been tested and used extensively with the older population. It is a brief questionnaire in which participants are asked ...

It took Europe a lot longer than the US or the UK to do these things, and you need only look at Greece one of the few countries that actually has endured a Depression-scale slump over the past ...

Anxiety and depression frequently occur and often coexist ... by assessing patients with the Hospital Anxiety and Depression Scale (HADS). In total, 422 patients with PD and 98 control individuals ...

The primary efficacy outcome was the response to treatment, which was defined as an at least 50% decrease on a depression scale from baseline to the end of treatment. Secondary efficacy outcomes ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 20% aftermarket. The company said the ...